SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Vincent van Gogh

PatientVincent van Gogh
Date of birth1990-03-30
IdentifiersMRN HR-NI010-SYN; SSN (made up) 000-10-3198
Document date2026-07-20
AuthorElise Verhoeven, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-month review: diagnosis, relapse prevention, movement check, and alcohol. [S]

History of Present Illness

Mr. van Gogh returns six months after his first visit. He has had no psychotic symptoms for more than four months and no racing ideas since the spring. He takes aripiprazole 10 mg and naltrexone daily. He sleeps seven hours. He is painting every day and preparing work for a small exhibition. He drinks a glass of wine with dinner on some days and none on others. His mood is good. The care coordinator's monthly PHQ-9 calls have been in the low range. He has had no thoughts of suicide or self-harm. His hepatitis C antibody from the preventive visit was nonreactive. [S]

ElementDetail
Psychotic symptomsNone for more than four months
MoodGood; PHQ-9 3
SleepSeven hours at regular times
AlcoholA glass of wine with dinner on some days
Hepatitis C antibodyNonreactive

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy good; weight stable
NeurologicalNegativeNo restlessness, stiffness, tremor, abnormal movements, or seizures
PsychiatricNegativeNo voices, suspiciousness, or racing ideas; mood good; no thoughts of suicide or self-harm

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Aripiprazole 10 mg oral tablet, one tablet by mouth once daily (started in hospital)One tablet by mouth once dailyOral route2026-01-05 to 2026-02-02completedS
Aripiprazole 15 mg oral tablet, one tablet by mouth once dailyOne tablet by mouth once dailyOral route2026-02-02 to 2026-02-16completedS
Naltrexone 50 mg oral tablet, one tablet by mouth once dailyOne tablet by mouth once dailyOral route2026-02-02activeS
Thiamine 100 mg oral tablet, one tablet by mouth daily (started in hospital)One tablet by mouth dailyOral route2026-01-05 to 2026-07-20completedS
Aripiprazole 10 mg oral tablet, one tablet by mouth once dailyOne tablet by mouth once dailyOral route2026-02-16activeS
Propranolol 10 mg oral tablet, one tablet by mouth twice daily for akathisiaOne tablet by mouth twice dailyOral route2026-02-16 to 2026-03-02completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-07-20Body height170cmS
2026-07-20Body weight65.4kgS
2026-07-20Body mass index (BMI) [Ratio]22.6kg/m2S
2026-07-20Systolic blood pressure118mm[Hg]S
2026-07-20Diastolic blood pressure76mm[Hg]S
2026-07-20Heart rate70/minS
2026-07-20Respiratory rate14/minS
2026-07-20Body temperature36.6CelS
2026-07-20Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-07-20Leukocytes [#/volume] in Blood by Automated count6.410*3/uL4-11 10*3/uLNormalS
2026-07-20Hemoglobin [Mass/volume] in Blood14.6g/dL13.2-16.6 g/dLNormalS
2026-07-20MCV [Entitic mean volume] in Red Blood Cells by Automated count95fL80-100 fLNormalS
2026-07-20Platelets [#/volume] in Blood by Automated count21410*3/uL150-400 10*3/uLNormalS
2026-07-20Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L10-40 U/LNormalS
2026-07-20Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L7-56 U/LNormalS
2026-07-20Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma36U/L8-61 U/LNormalS
2026-07-20Phosphatidylethanol [Mass/volume] in Blood16ng/mLBelow 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinkingNormalS
2026-07-20Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S

Physical Exam

Vital signs recorded on 2026-07-20; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 65.4 kg; blood pressure 118/76, pulse 70
NeurologicalAIMS score 0: no abnormal movements of the face, lips, jaw, tongue, limbs, or trunk; no akathisia or rigidity
PsychiatricEuthymic and engaged; organized; no psychotic features

Problems

ProblemClinical statusVerificationCodeProvenance
First episode of psychosis with mood features: weeks of very little sleep, intense work and expansive plans, then acute confusion, hallucinations and suspiciousness with self-injury, and low mood since discharge. Diagnosis provisional; differential: bipolar I disorder with psychotic features, brief psychotic or schizophreniform disorder, alcohol withdrawal delirium or alcohol-induced psychotic disorder, and psychosis related to focal epilepsy. Synthetic modern episode linked to his documented first crisisactiveprovisional F29S — Synthetic modern coding of the documented first crisis. Unspecified psychosis is coded because the cause is not yet established; the retrospective diagnoses stay in the claims.
Alcohol use disorder, moderate (heavy daily wine and anise spirits before the episode); synthetic modern episode linked to his documented heavy drinkingactiveconfirmed F10.20S — Synthetic modern coding of the documented drinking and its retrospective interpretation.
Self-injury to the left ear during the acute confusional episode, without suicidal intent; wound healed after surgical care in hospitalactiveconfirmed Z91.52S — Synthetic modern coding of the documented injury; no detail of the injury is recorded.
Akathisia from aripiprazole, two weeks after the dose was increased to 15 mg; treated by returning to 10 mg and short-term propranolol; resolvedresolvedconfirmed G25.71S — Synthetic medication side effect; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyAntipsychotic dose, adherence, and responseEvery visitCompleted todayAripiprazole 10 mg; full adherence; full remission
SurveyPsychotic and mood symptoms, and early warning signsEvery visitCompleted todayNo psychotic or mood symptoms; no early warning signs
ExaminationAkathisia, parkinsonism, and sedationEvery visit in the first months and after any dose changeCompleted todayNone
ExaminationAbnormal Involuntary Movement Scale (AIMS)Baseline, then every 6 monthsCompleted todayAIMS score 0 at six months; repeat in six months
ExaminationWeight and BMIEvery visit for 6 months after starting, then quarterly (CMID: baseline, 4, 8, and 12 weeks, then quarterly)Completed today65.4 kg, up 2.2% from intake; quarterly from now
ExaminationBlood pressureBaseline, 12 weeks, then yearlyCompleted today118/76
LaboratoryFasting glucose and A1cBaseline, 12 weeks to 4 months, then yearlyUp to dateNormal at the three-month visit; next in a year
LaboratoryFasting lipid panelBaseline, 12 weeks to 4 months, then yearlyUp to dateNormal at the three-month visit; next in a year
SurveyDepression measure (PHQ-9)Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodicallyCompleted todayPHQ-9 3, from 13 at intake: remission
SurveyMood Disorder QuestionnaireWhen a new depressive episode is evaluatedNot indicatedNo depressive episode now; the possibility of bipolar disorder is followed through the mood history at each visit
SurveySuicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; safety plan and psychiatric advance directive current; the 988 Suicide & Crisis Lifeline in his phone
Self-managementSleepEvery visitCompleted todaySeven hours at regular times
SurveyDrinking (AUDIT-C and PEth)PEth at intake and at each check while drinking continues; AUDIT-C yearlyCompleted todayPEth 16 ng/mL; AUDIT-C 3 at the preventive visit
Medication safetyNaltrexone: liver tests and opioid exposureLiver tests before starting, then at 1 to 3 months and every 6 to 12 monthsCompleted todayAST 27, ALT 26, GGT 36 U/L, normal
LaboratoryBlood countAt intake and with liver tests while drinkingCompleted todayWhite cells 6.4, hemoglobin 14.6 g/dL, MCV 95 fL (from 102), platelets 214
Medication safetyThiamineWhile drinking heavilyCompleted todayStopped today
Self-managementHepatitis B vaccineTwo doses at least four weeks apartCompleted todayDose 2 given today; series complete
Self-managementCoordinated specialty care engagementOngoing, for up to two to three yearsCompleted todayTherapist every two weeks; peer specialist monthly; exhibition planned

Goal progress:

Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2 [S]

Guideline basis: The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020); Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018); Consensus development conference on antipsychotic drugs and obesity and diabetes (2004); Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); Adult Immunization Schedule by Medical Condition and Other Indication (2026)

Follow-up: Visits every three months with weight and the PHQ-9. Psychiatry review with Dr. Feld near the one-year mark about the length of antipsychotic treatment. AIMS in six months; glucose, A1c and lipids in a year. Influenza and COVID-19 vaccines in the autumn. [S]